The authors of the study conclude that “KAT offers clinically meaningful improvements and demonstrated a desirable safety and risk mitigation profile”. Ongoing ketamine-based medication sessions enhance therapeutic benefits by preventing the 90% relapse rate that is often seen in single-infusion ketamine-based treatments (Kryst et al., 2020).

Hull et al. (2022) take this standpoint to reiterate the use of dissociative and psychedelic compounds for reducing important symptoms of common mental health disorders such as reducing suicidal ideation and behaviour. This could be viewed as an exaggeration, especially since the mechanism of dissociation is still relatively unknown in terms of how it reduces anxiety and depression symptoms (Liu et al., 2020).